GH-releasing peptide-2 increases fat mass in mice lacking NPY: Indication for a crucial mediating role of hypothalamic agouti-related protein

Endocrinology

Volumn 143, Issue 2, 2002, Pages 558-568

  Tschöp, Matthias ^a   Statnick, Michael A ^a   Suter, Todd M ^a   Heiman, Mark L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; GHRELIN; GHRELIN RECEPTOR AGONIST; NEUROPEPTIDE Y; PRALMORELIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANOREXIA NERVOSA; ARTICLE; BODY FAT; BODY WEIGHT; CACHEXIA; CONTROLLED STUDY; ENERGY BALANCE; FOOD INTAKE; GROWTH HORMONE RELEASE; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; WASTING SYNDROME;

EID: 0036150931     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.143.2.8633     Document Type: Article

References (61)

1. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro
2. A nonpeptidyl growth hormone secretagogue
3. A receptor in pituitary and hypothalamus that functions in growth hormone release
4. Co-localization of growth hormone secretagoguer receptor and NPY mRNA in the arcuate nucleus of the rat
5. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues
6. Growth hormone secretagogue binding sites in peripheral human tissues
7. Ghrelin is a growth-hormone-releasing acylated peptide from stomach
8. Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor
9. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans
10. Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats
11. Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans
12. Ghrelin-induced growth hormone secretion in humans
13. Positional cloning of the mouse obese gene and its human homologue
14. Obesity and the regulation of energy balance
15. Molecular regulation of eating behavior: New insights and prospects for therapeutic strategies
16. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
17. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons
18. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6
19. Chronic central infusion of growth hormone secretagogues: Effects on fos expression and peptide gene expression in the rat arcuate nucleus
20. Activation of arcuate nucleus neurons by systemic administration of leptin and growth hormone-releasing peptide-6 in normal and fasted rats
21. Growth hormone secretagogue activation of the arcuate nucleus and brainstem occurs via a non-noradrenergic pathway
22. Ghrelin induces adiposity in rodents
23. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion
24. A role for ghrelin in the central regulation of feeding
25. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway
26. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin
27. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y
28. Life without neuropeptide Y
29. Design, synthesis, and biological activity of peptides which release growth hormone in vitro
30. Use and storage of carbohydrate and fat
31. Whole body composition of rats determined by dual energy X-ray absorptiometry is correlated with chemical analysis
32. Energy expenditure and fuel selection in biological systems: The theory and practice of calculations based on indirect calorimetry and tracer methods
33. Soft tissue composition and bone mineral status: Evaluation by dual-energy X-ray absorptiometry
34. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons
35. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats
36. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature
37. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
38. Effects of exogenous growth hormone on growth and body composition in genetically selected mice
39. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: A comparison with normal subjects and patients with hypo-pituitarism or critical illness
40. Hormonal regulation of protein metabolism in relation to nutrition and disease
41. Growth hormone secretagogue actions on the pituitary gland: Multiple receptors for multiple ligands?
42. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse
43. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass
44. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: Evidence of a cellular basis for the adipostat
45. Neuroendocrine regulation by the Agouti/Agrp-melanocortin system
46. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression
47. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome
48. Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade
49. Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat
50. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males
51. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity
52. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance
53. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
54. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats
55. The osteoblast: A sophisticated fibroblast under central surveillance
56. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass
57. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
58. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness
59. The pathophysiology of wasting in the elderly
60. Treatments for wasting in patients with the acquired immunodeficiency syndrome
61. Cancer anorexia-cachexia syndrome: Are neuropeptides the key?